全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
BMC Cancer  2004 

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

DOI: 10.1186/1471-2407-4-56

Full-Text   Cite this paper   Add to My Lib

Abstract:

Tipifarnib-mediated gene expression changes in 3 AML cell lines and bone marrow samples from two patients with AML were analyzed on a cDNA microarray containing approximately 7000 human genes. Pathways associated with these expression changes were identified using the Ingenuity Pathway Analysis tool.The expression analysis identified a common set of genes that were regulated by tipifarnib in three leukemic cell lines and in leukemic blast cells isolated from two patients who had been treated with tipifarnib. Association of modulated genes with biological functional groups identified several pathways affected by tipifarnib including cell signaling, cytoskeletal organization, immunity, and apoptosis. Gene expression changes were verified in a subset of genes using real time RT-PCR. Additionally, regulation of apoptotic genes was found to correlate with increased Annexin V staining in the THP-1 cell line but not in the HL-60 cell line.The genetic networks derived from these studies illuminate some of the biological pathways affected by FTI treatment while providing a proof of principle for identifying candidate genes that might be used as surrogate biomarkers of drug activity.The investigative agent tipifarnib is a member of a new class of drugs that were designed to function as a non-peptidomimetic competitive farnesyltransferase inhibitor (FTI). The principal behind this drug class is that protein farnesylation is required for many cell-signaling processes and that dysregulation of cell signaling is thought to be instrumental in driving cell proliferation in several malignancies. The hypothesis that gave rise to this exciting class of drugs is that the inhibition of this enzyme would reduce the uncontrolled cell signaling and provide some control over cell division and malignant cell proliferation.In hematological cancers, tipifarnib has shown significant inhibition of the proliferation of a variety of human tumor cell lines both in vitro and in vivo [1-3]. A recent

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133